Medicare Enrolled
Dr. Jonathan Greifenkamp, MD
Cardiovascular Disease · Longview, TX
Practice pattern: Cardiac Imaging— Practice with significant diagnostic imaging and stress testing
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Greifenkamp from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Greifenkamp? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Greifenkamp
Dr. Jonathan Greifenkamp is a cardiovascular disease in Longview, TX, with 18 years in practice. Based on federal Medicare data, Dr. Greifenkamp performed 5,331 Medicare services across 3,923 unique beneficiaries.
Between the years covered by Open Payments, Dr. Greifenkamp received a total of $16,529 from 40 pharmaceutical and/or device companies across 903 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Greifenkamp is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 15% volume in TX$ $16,529 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,331
Medicare services
Top 15% in TX for cardiovascular disease
3,923
Unique beneficiaries
$86
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~296 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Regadenoson injection (Lexiscan) for heart stress test | 852 | $44 | $152 |
| Office visit, established patient (30-39 min) | 417 | $83 | $287 |
| Office visit, established patient (20-29 min) | 373 | $63 | $195 |
| Echocardiogram, transthoracic | 335 | $140 | $599 |
| Electrocardiogram (EKG), 12-lead | 269 | $9 | $45 |
| Heart muscle strain imaging | 245 | $28 | $107 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 242 | $101 | $1,727 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 239 | $47 | $203 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 237 | $328 | $1,273 |
| Remote pacemaker monitoring, 90 days | 179 | $22 | $92 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 177 | $127 | $516 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 143 | $18 | $72 |
| Prothrombin time test (blood clotting) | 124 | $4 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 116 | $5 | $22 |
| New patient office visit (45-59 min) | 114 | $114 | $439 |
| Anticoagulant management of patient taking warfarin | 109 | $8 | $34 |
| EKG interpretation and report | 102 | $6 | $23 |
| Office visit, established patient (10-19 min) | 91 | $42 | $116 |
| Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 87 | $10 | $13 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 86 | $83 | $314 |
| Cardiac catheterization | 84 | $176 | $819 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 62 | $26 | $184 |
| Coronary stent placement | 61 | $359 | $1,628 |
| Hospital follow-up visit, moderate complexity | 59 | $62 | $196 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 58 | $19 | $71 |
| New patient office visit (30-44 min) | 55 | $65 | $288 |
| Programming of dual lead pacemaker system | 38 | $55 | $156 |
| Ultrasound of leg arteries or artery grafts | 35 | $142 | $572 |
| Chemical destruction of first incompetent vein of arm or leg using imaging guidance | 33 | $1,295 | $5,589 |
| Ultrasound of both sides of head and neck blood flow | 29 | $119 | $448 |
| Initial hospital admission, moderate complexity | 28 | $102 | $371 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 24 | $148 | $664 |
| Removal of plaque in arteries of leg | 23 | $381 | $1,682 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 23 | $186 | $928 |
| Removal of varicose veins of arm or leg, 10-20 incisions | 22 | $164 | $1,748 |
| Ultrasound of heart, follow-up | 20 | $71 | $327 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 20 | $241 | $1,039 |
| Review by radiologist of additional artery image | 18 | $35 | $48 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 18 | $43 | $263 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 16 | $17 | $67 |
| Insertion of needle or tube into artery of arm or leg | 14 | $34 | $249 |
| Review by radiologist of arm or leg artery image | 14 | $61 | $153 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 14 | $9 | $40 |
| Initial hospital admission, high complexity | 13 | $136 | $549 |
| Hospital follow-up visit, low complexity | 13 | $39 | $106 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
14.7% high complexity
37.0% medium
48.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,529
Total received (2018-2024)
Avg $2,361/year across 7 years
Top 22% in TX for cardiovascular disease
40
Companies
903
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,529 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,607
2023$3,114
2022$2,604
2021$3,088
2020$1,829
2019$1,537
2018$1,751
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Abbott Laboratories
$2,675
Biosense Webster, Inc.
$1,565
Bard Peripheral Vascular, Inc.
$1,322
Edwards Lifesciences Corporation
$1,247
Medtronic Vascular, Inc.
$1,197
Novartis Pharmaceuticals Corporation
$1,144
Medtronic, Inc.
$1,053
W. L. Gore & Associates, Inc.
$678
Boston Scientific Corporation
$587
Janssen Pharmaceuticals, Inc
$530
E.R. Squibb & Sons, L.L.C.
$500
ShockWave Medical, Inc
$462
Amgen Inc.
$396
Inari Medical, Inc.
$381
Merck Sharp & Dohme LLC
$331
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$326
Cardiovascular Systems Inc.
$326
Gilead Sciences, Inc.
$262
Alnylam Pharmaceuticals Inc.
$257
AstraZeneca Pharmaceuticals LP
$175
Shockwave Medical, Inc
$159
SANOFI-AVENTIS U.S. LLC
$126
Penumbra, Inc.
$112
ABIOMED
$105
Itamar Medical Inc
$103
PFIZER INC.
$77
Philips Electronics North America Corporation
$68
BOSTON SCIENTIFIC CORPORATION
$60
SCPHARMACEUTICALS INC.
$56
Boehringer Ingelheim Pharmaceuticals, Inc.
$44
Novo Nordisk Inc
$36
Teleflex LLC
$31
Chiesi USA, Inc.
$30
Cook Medical LLC
$19
Silk Road Medical, Inc.
$17
Amarin Pharma Inc.
$16
Terumo Medical Corporation
$16
BIOTRONIK INC.
$15
Acist Medical Systems, Inc.
$14
CashFlow Solutions, LLC
$13
Top 3 companies account for 33.6% of total payments
Associated products mentioned in payments ›
(5027) Intact Vascular Und · 3F · AMPLATZER Occluders · ASSURITY · ATTAIN COMMAND + SUREVALVE · AZURE XT DR MRI SURESCAN · Amplia MRI · Asahi Fielder XT cornary guide wire · Asahi Fielder coronary guide wire · Asahi Sion guide wire · Assurity Pacemaker · BRILINTA · Baylis Medical Company Radiofrequency Puncture Generator · BodyGuardian · CAMZYOS · CARDIOMEMS · CARTO 3 · COBALT DR MRI SURESCAN · Carto 3 · Carto 3 System · CartoSound · ClosureFast · Cobalt · Confidense · Confirm Rx · Cook Medical Flexor Ansel · CoreValve Evolut · Corlanor · DIAMONDBACK PERIPHERAL · Diamondback Coronary · Diamondback Peripheral · Durata Defibrillation ICD Lead · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · ENROUTE .014 Guidewire · ENSITE · ENTRESTO · ESPRIT · EXCLUDER Conformable AAA Endoprosthesis with Active Control · Edwards SAPIEN 3 Transcatheter Heart Valve · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · FARXIGA · FLOWTRIEVER CATHETER · FUROSCIX · GALLANT · GORE DRYSEAL FLEX Introducer Sheath · GORE EXCLUDER Iliac Branch Endoprosthesis · GORE TAG Conformable Thoracic Endoprosthesis · GORE TAG Thoracic Endoprosthesis · GORE VIABAHN Endoprosthesis with Heparin · GORE VIABAHN VBX Balloon Expandable Endo · GuideLiner V3 Catheter · HAWKONE · Hi-Torque Cross-It guide wires · Hi-Torque Pilot guide wire · IGT D Peripheral · INSPIRIS RESILIA AORTIC VALVE · Impella · Indigo · Interventional Products · JARDIANCE · KENGREAL · LEQVIO · LINQ II · LOKELMA · LUTONIX · LYMPHA PRESS OPTIMAL PLUS(US) BT · LifeVest · Lutonix Drug Coated Balloon · MERLIN@HOME · MICRA · MITRACLIP · MULTAQ · Merlin Connectivity and Remote · Micra · Mini Trek catheters · Misago · MitraClip System · Multi-Link Mini Vision coronary stent system · NC TREK coronary catheters · OMNILINK ELITE · ONPATTRO · Optisure Defibrillation ICD Lead · Ozempic · PERCLOSE PROSTYLE · PRALUENT · PROMUS · Pacemakers · Peripheral Orbital Atherectomy System · Quadra Allure MP RF CRT Pacemkr · RXi Systems · Repatha · Resolute · Reveal LINQ · S · SAPIEN 3 Ultra RESILIA · SHOCKWAVE IVL SYSTEM WITH THE SHOCKWAVE C2 CORONARY IVL CATHETER · SUPERA · Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter · Soundstar · TYRX · Tendril Pacing Lead · ULTRASCORE · Unify Assura CRT Defibrillator · VERQUVO · Valiant Captivia · Vascepa · VenaSeal · VersaCross Access Solution · VersaCross Steerable Access Solution · WATCHMAN · WATCHMAN Access System · WATCHMAN FLX · WOLVERINE · WatchPAT · WatchPATONE · XARELTO · Xience Alpine cornary stent system · Xience Sierra Coronary Stent System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $310 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
10
Per 100K population
8.0
County median income
$64,809
Nearest hospital
LONGVIEW REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Greifenkamp is a cardiac imaging specialist, with above-average Medicare volume (top 15% in TX), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Greifenkamp experienced with regadenoson injection (lexiscan) for heart stress test?
Based on Medicare claims data, Dr. Greifenkamp performed 852 regadenoson injection (lexiscan) for heart stress test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Greifenkamp receive payments from pharmaceutical companies?
Yes. Dr. Greifenkamp received a total of $16,529 from 40 companies across 903 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Greifenkamp's costs compare to other cardiovascular diseases in Longview?
Dr. Greifenkamp's average Medicare payment per service is $86. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Greifenkamp) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Longview
Browse cardiovascular diseases in Longview ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
By company
Biosense Webster, Inc. Payments to Doctors
See all physicians who received payments from Biosense Webster, Inc..
By company
Bard Peripheral Vascular, Inc. Payments to Doctors
See all physicians who received payments from Bard Peripheral Vascular, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology